Melanoma Clinical Trials in Los Angeles

Showing 61-80 of 201 trials

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05585034

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.

Head and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal MelanomaNon-small Cell Lung Cancer, Squamous or Non-squamous+6 more

Xencor, Inc.60 participantsStarted Dec 2022

Los Angeles, California, United States • Denver, Colorado, United States • Sarasota, Florida, United States +9 more locations

COMPLETEDPhase 1< 1 mile

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

NCT02680184

This study will be conducted in two parts: Part 1 will be conducted using a Dose Escalation and Expansion design. The Part 1 Dose Escalation Phase of this study will identify a safe and tolerable dose to be further evaluated in the Part 1 Dose Expansion phase. Part 2 of the study will be conducted in parallel with the Part 1 Dose Expansion Phase and will evaluate the safety and efficacy of CMP-001 when administered as a monotherapy. A Treatment Extension to assess the safety profile of CMP-001 when given in combination with pembrolizumab or as monotherapy will be available to those who are currently being treated in either Part 1 or Part 2 of this study at the time of protocol Amendment 9, v10.0.

Melanoma

Regeneron Pharmaceuticals199 participantsStarted Apr 2016

Phoenix, Arizona, United States • Tucson, Arizona, United States • Duarte, California, United States +10 more locations

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Melanoma Trials in Other Cities

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

A Study of SEA-CD40 Given With Other Drugs in Cancers

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

MGC018 With or Without MGA012 in Advanced Solid Tumors

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Other Conditions in Los Angeles